The global human and animal vaccine adjuvants market size is expected to reach at USD 1.07 billion by 2025. High prevalence of diseases and rising research activities in developing regions are anticipated to propel market growth over the forecast period.
Development and manufacturing of adjuvants is mostly carried out at established facilities in developed countries. However, transferring vaccine technologies to developing countries will help in targeting emerging diseases and will enable mass production. This factor will also ease getting regulatory approvals, as antigen and vaccines cab be manufactured locally.
Vaccine manufacturers present in developing countries play a significant role in development and manufacturing of vaccines. For instance, in 2017, Serum Institute of India produced 1.2 billion doses, making it the leading manufacturer in the world. Transferring vaccine technology to developing nations will help manufacturers develop innovative vaccines against challenging illnesses that are not a prevalent in the developed world. Furthermore, this provision presents a cost-effective alternative since labor and materials are less expensive in developing countries.
Increasing need for efficient immunization is expected to boost the demand for new human and animal vaccine adjuvants. Conventional vaccine adjuvants, such as alum is less effective against fatal diseases, therefore, key market players are focusing on introducing new and effective products. Many other adjuvants are under clinical trials and are expected to be registered in the forthcoming years. This factor is anticipated to bode well for the expansion of the global human and animal vaccine adjuvants market in near future.
For instance, CpG (TLR 9 agonist) vaccine adjuvant from InvivoGen Inc. The product is in Phase III of clinical trial. It is CD8 T cell-mediated immunity and Th1 type immunity. Others include SAPONEX, a synthetic version of QS-21, under phase III trials. It was recently approved for use in GSK’s pediatric malaria vaccine Mosquirix.
Advance form of these products are Nano particle and recombinant vector vaccine adjuvants. For instance, CaPtivant is working on development of calcium phosphate nanoparticle vaccine adjuvants. This technology helps in enhancing immune response against parasitic, bacterial, and viral antigens. Saponin-based adjuvants at different various developmental stages. Desert King International is a leading producer of food grade saponin in the world. The company supplies pure saponin extract, rich in QS-21 for pharmaceutical applications. With its Quillaja saponaria forestry operations and production facility in Chile, the company has established a robust, integrated supply chain to ensure quality extracts.
Many companies, such as Brenntag Biosector A/S, are engaged in R&D activities to develop Saponin-based adjuvants. Major players operating in the human and animal vaccine adjuvants market such as GlaxoSmithKline (GSK) plc, held major shares in U.S. and Europe markets. In October 2017, GSK received the U.S. Food and Drug Administration (FDA) approval for the sale of Shingrix for the prevention of shingles.
Some of the prominent companies in the market include Adjuvance Technologies, Inc.; Novavax, Inc.; and InvivoGen. Most companies focus on development of cancer and HIV vaccines. They are engaging in mergers and acquisitions to strengthen their position in emerging markets, such as India, China, and Mexico. For instance, in September 2015, GSK acquired Novartis Vaccine and divested its marketed oncology portfolio to Novartis India. Moreover, in July 2015, bioCSL and influenza vaccines unit of Novartis came together to form Seqirus, which is now among leading influenza vaccine companies in the world.